<p>Aardvark Therapeutics, Inc.（NASDAQ:AARD - 获取免费报告）在目前覆盖该股票的十一家评级公司中被评为 “适度买入”，Marketbeat.com 报道。一位研究分析师给予该股票卖出评级，九位分析师给予买入评级，还有一位分析师给予强烈买入评级。在过去一年中，更新了对该股票覆盖的经纪公司中，平均的十二个月目标价格为 32.4444 美元。</p>
<p>获取 <strong>Aardvark Therapeutics</strong> 的提醒：</p>
<p>最近，一些研究分析师对 AARD 股票发布了报告。Cantor Fitzgerald 在 11 月 14 日的报告中重申了对 Aardvark Therapeutics 股票的 “增持” 评级。Jones Trading 于 10 月 1 日的研究报告中开始覆盖 Aardvark Therapeutics 股票。他们为该公司设定了 “买入” 评级和 33.00 美元的价格目标。美国银行在 8 月 28 日的研究报告中将 Aardvark Therapeutics 股票的价格目标从 26.00 美元下调至 25.00 美元，并对该股票设定了 “买入” 评级。加拿大皇家银行在 11 月 14 日的报告中将 Aardvark Therapeutics 股票的价格目标从 19.00 美元下调至 18.00 美元，并对该股票设定了 “跑赢大盘” 评级。最后，William Blair 于 12 月 12 日的研究报告中开始覆盖 Aardvark Therapeutics 股票。他们为该公司设定了 “跑赢大盘” 评级。</p>
<p><strong>获取我们最新的 AARD 股票分析</strong></p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席财务官 Nelson Sun 于 12 月 11 日以每股 14.40 美元的平均成本购买了 3,000 股该公司的股票，总交易额为 43,200.00 美元。交易后，首席财务官直接持有该公司 108,484 股股票，价值约为 1,562,169.60 美元。这笔交易代表了他们持股比例的 2.84% 的增加。该购买在向 SEC 提交的文件中披露，相关文件可通过此超链接获取。此外，首席执行官 Tien-Li Lee 于 12 月 11 日以每股 14.48 美元的平均成本购买了 7,000 股该公司的股票，总价值为 101,360.00 美元。购买后，首席执行官持有该公司 1,551,613 股股票，价值约为 22,467,356.24 美元。这笔交易代表了他们持股比例的 0.45% 的增加。有关此购买的更多细节可在官方 SEC 披露中找到。</p>
<h2>机构投资者对 Aardvark Therapeutics 的看法</h2>
<p>对该公司的对冲基金最近对其持仓进行了调整。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度购买了 Aardvark Therapeutics 的新头寸，价值约为 42,000 美元。纽约州共同退休基金在第二季度购买了 Aardvark Therapeutics 股票的新股份，价值约为 99,000 美元。美国银行在第二季度将其在 Aardvark Therapeutics 股票中的持仓增加了 72.9%。美国银行现在持有该公司 7,989 股股票，价值 108,000 美元，此前在上个季度又收购了 3,369 股。Walleye Capital LLC 在第一季度购买了 Aardvark Therapeutics 股票的新头寸，价值约为 88,000 美元。最后，高盛集团在第一季度购买了 Aardvark Therapeutics 的新头寸，价值 153,000 美元。</p>
<h2>Aardvark Therapeutics 股票表现</h2>
<p>NASDAQ AARD 股票周一开盘价为 13.77 美元。该公司的 50 日简单移动平均线为 11.62 美元，200 日简单移动平均线为 11.82 美元。Aardvark Therapeutics 的 52 周低点为 4.88 美元，52 周高点为 19.58 美元。该公司的市值为 2.9977 亿美元，市盈率为-6.50。</p>
<p>Aardvark Therapeutics（NASDAQ:AARD - 获取免费报告）最后一次发布财报是在 11 月 13 日。该公司报告季度每股收益为（0.75 美元），超出分析师一致预期的（0.82 美元）0.07 美元。</p>
<h2>关于 Aardvark Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Aardvark Therapeutics, Inc 是一家总部位于马萨诸塞州剑桥的临床阶段生物制药公司，专注于小分子调节剂的发现和开发，这些调节剂作用于视黄酸受体相关孤儿受体伽马（RORγ）。RORγ 在 T 辅助 17（Th17）细胞分化和炎症过程中发挥核心作用。通过靶向这一转录因子，Aardvark 旨在解决一系列自身免疫和免疫介导的疾病。</p>
<p>该公司的主要项目包括选择性 RORγ 反向激动剂，旨在抑制在银屑病、炎症性肠病和其他慢性炎症疾病等病症中由 Th17 驱动的致病性反应。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Aardvark Therapeutics</li>
<li>我不应该把这个发给你</li>
<li>揭示：美国刚刚解锁了 500 万亿美元的资产</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>他们嘲笑 30 美元。他们不会再嘲笑 70 美元。</li>
<li>100 万美元在退休后能维持多久？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFSRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFSRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Aardvark Therapeutics 吗？</h2>
<p>在你考虑 Aardvark Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Aardvark Therapeutics 并不在名单上。</p>
<p>虽然 Aardvark Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AARD

<p>Aardvark Therapeutics, Inc.（纳斯达克代码：AARD）获得了十一位分析师的 “适度买入” 共识评级。平均十二个月目标价格为 32.44 美元。最近的分析师评级包括 Cantor Fitzgerald 的 “增持”、Jones Trading 的 “买入”，以及加拿大皇家银行和威廉·布莱尔的 “跑赢大盘”。首席财务官 Nelson Sun 和首席执行官 Tien-Li Lee 最近增加了他们的股票持有量。机构投资者也进行了新的投资。该公司的股票在周一以 13.77 美元开盘，市值为 2.9977 亿美元</p>

<p>Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has been assigned an average rating of &#34;Moderate Buy&#34; from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $32.4444.</p>
<div class="lb-trans"><p>Aardvark Therapeutics, Inc.（NASDAQ:AARD - 获取免费报告）在目前覆盖该股票的十一家评级公司中被评为 “适度买入”，Marketbeat.com 报道。一位研究分析师给予该股票卖出评级，九位分析师给予买入评级，还有一位分析师给予强烈买入评级。在过去一年中，更新了对该股票覆盖的经纪公司中，平均的十二个月目标价格为 32.4444 美元。</p>
</div><p>Get <strong>Aardvark Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aardvark Therapeutics</strong> 的提醒：</p>
</div><p>A number of research analysts have recently issued reports on AARD shares. Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Aardvark Therapeutics in a report on Friday, November 14th. Jones Trading began coverage on shares of Aardvark Therapeutics in a research report on Wednesday, October 1st. They set a &#34;buy&#34; rating and a $33.00 price target for the company. Bank of America lowered their price objective on shares of Aardvark Therapeutics from $26.00 to $25.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, August 28th. Royal Bank Of Canada dropped their price objective on shares of Aardvark Therapeutics from $19.00 to $18.00 and set an &#34;outperform&#34; rating on the stock in a report on Friday, November 14th. Finally, William Blair started coverage on shares of Aardvark Therapeutics in a research report on Friday, December 12th. They set an &#34;outperform&#34; rating for the company.</p>
<div class="lb-trans"><p>最近，一些研究分析师对 AARD 股票发布了报告。Cantor Fitzgerald 在 11 月 14 日的报告中重申了对 Aardvark Therapeutics 股票的 “增持” 评级。Jones Trading 于 10 月 1 日的研究报告中开始覆盖 Aardvark Therapeutics 股票。他们为该公司设定了 “买入” 评级和 33.00 美元的价格目标。美国银行在 8 月 28 日的研究报告中将 Aardvark Therapeutics 股票的价格目标从 26.00 美元下调至 25.00 美元，并对该股票设定了 “买入” 评级。加拿大皇家银行在 11 月 14 日的报告中将 Aardvark Therapeutics 股票的价格目标从 19.00 美元下调至 18.00 美元，并对该股票设定了 “跑赢大盘” 评级。最后，William Blair 于 12 月 12 日的研究报告中开始覆盖 Aardvark Therapeutics 股票。他们为该公司设定了 “跑赢大盘” 评级。</p>
</div><p><strong>Get Our Latest Stock Analysis on AARD</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 AARD 股票分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CFO Nelson Sun acquired 3,000 shares of the firm's stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $14.40 per share, for a total transaction of $43,200.00. Following the transaction, the chief financial officer directly owned 108,484 shares of the company's stock, valued at approximately $1,562,169.60. This trade represents a 2.84% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Tien-Li Lee acquired 7,000 shares of the company's stock in a transaction dated Thursday, December 11th. The stock was acquired at an average cost of $14.48 per share, with a total value of $101,360.00. Following the purchase, the chief executive officer owned 1,551,613 shares of the company's stock, valued at approximately $22,467,356.24. This trade represents a 0.45% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.</p>
<div class="lb-trans"><p>在其他新闻中，首席财务官 Nelson Sun 于 12 月 11 日以每股 14.40 美元的平均成本购买了 3,000 股该公司的股票，总交易额为 43,200.00 美元。交易后，首席财务官直接持有该公司 108,484 股股票，价值约为 1,562,169.60 美元。这笔交易代表了他们持股比例的 2.84% 的增加。该购买在向 SEC 提交的文件中披露，相关文件可通过此超链接获取。此外，首席执行官 Tien-Li Lee 于 12 月 11 日以每股 14.48 美元的平均成本购买了 7,000 股该公司的股票，总价值为 101,360.00 美元。购买后，首席执行官持有该公司 1,551,613 股股票，价值约为 22,467,356.24 美元。这笔交易代表了他们持股比例的 0.45% 的增加。有关此购买的更多细节可在官方 SEC 披露中找到。</p>
</div><h2>Institutional Investors Weigh In On Aardvark Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Aardvark Therapeutics 的看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Aardvark Therapeutics during the second quarter valued at approximately $42,000. New York State Common Retirement Fund purchased a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth approximately $99,000. Bank of America Corp DE boosted its position in shares of Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock valued at $108,000 after acquiring an additional 3,369 shares during the last quarter. Walleye Capital LLC bought a new position in shares of Aardvark Therapeutics during the 1st quarter valued at approximately $88,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Aardvark Therapeutics in the first quarter valued at $153,000.</p>
<div class="lb-trans"><p>对该公司的对冲基金最近对其持仓进行了调整。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度购买了 Aardvark Therapeutics 的新头寸，价值约为 42,000 美元。纽约州共同退休基金在第二季度购买了 Aardvark Therapeutics 股票的新股份，价值约为 99,000 美元。美国银行在第二季度将其在 Aardvark Therapeutics 股票中的持仓增加了 72.9%。美国银行现在持有该公司 7,989 股股票，价值 108,000 美元，此前在上个季度又收购了 3,369 股。Walleye Capital LLC 在第一季度购买了 Aardvark Therapeutics 股票的新头寸，价值约为 88,000 美元。最后，高盛集团在第一季度购买了 Aardvark Therapeutics 的新头寸，价值 153,000 美元。</p>
</div><h2>Aardvark Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Aardvark Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ AARD opened at $13.77 on Monday. The company has a 50 day simple moving average of $11.62 and a two-hundred day simple moving average of $11.82. Aardvark Therapeutics has a fifty-two week low of $4.88 and a fifty-two week high of $19.58. The company has a market capitalization of $299.77 million and a price-to-earnings ratio of -6.50.</p>
<div class="lb-trans"><p>NASDAQ AARD 股票周一开盘价为 13.77 美元。该公司的 50 日简单移动平均线为 11.62 美元，200 日简单移动平均线为 11.82 美元。Aardvark Therapeutics 的 52 周低点为 4.88 美元，52 周高点为 19.58 美元。该公司的市值为 2.9977 亿美元，市盈率为-6.50。</p>
</div><p>Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($0.75) EPS for the quarter, topping analysts' consensus estimates of ($0.82) by $0.07.</p>
<div class="lb-trans"><p>Aardvark Therapeutics（NASDAQ:AARD - 获取免费报告）最后一次发布财报是在 11 月 13 日。该公司报告季度每股收益为（0.75 美元），超出分析师一致预期的（0.82 美元）0.07 美元。</p>
</div><h2>About Aardvark Therapeutics</h2>
<div class="lb-trans"><h2>关于 Aardvark Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.</p>
<div class="lb-trans"><p>Aardvark Therapeutics, Inc 是一家总部位于马萨诸塞州剑桥的临床阶段生物制药公司，专注于小分子调节剂的发现和开发，这些调节剂作用于视黄酸受体相关孤儿受体伽马（RORγ）。RORγ 在 T 辅助 17（Th17）细胞分化和炎症过程中发挥核心作用。通过靶向这一转录因子，Aardvark 旨在解决一系列自身免疫和免疫介导的疾病。</p>
</div><p>The company's lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.</p>
<div class="lb-trans"><p>该公司的主要项目包括选择性 RORγ 反向激动剂，旨在抑制在银屑病、炎症性肠病和其他慢性炎症疾病等病症中由 Th17 驱动的致病性反应。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Aardvark Therapeutics</li>
<li>I Shouldn't Be Sending You This</li>
<li>REVEALED: America just unlocked a $500 trillion asset</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>They Laughed at $30. They Won’t Laugh at $70.</li>
<li>How Long Will $1M Last in Retirement?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Aardvark Therapeutics</li>
<li>我不应该把这个发给你</li>
<li>揭示：美国刚刚解锁了 500 万亿美元的资产</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>他们嘲笑 30 美元。他们不会再嘲笑 70 美元。</li>
<li>100 万美元在退休后能维持多久？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFSRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=AARD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aardvark Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aardvark Therapeutics 吗？</h2>
</div><p>Before you consider Aardvark Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Aardvark Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Aardvark Therapeutics 并不在名单上。</p>
</div><p>While Aardvark Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aardvark Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aardvark Therapeutics, Inc.（NASDAQ:AARD）被分析师一致推荐为 “适度买入”